Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mylan NV (NASDAQ:MYL)

40.22
Delayed Data
As of 4:14pm ET
 -1.09 / -2.64%
Today’s Change
37.59
Today|||52-Week Range
55.51
-25.61%
Year-to-Date
Mylan (MYL) CEO Bresch Will Have to Explain EpiPen Profits, WSJ's Baker Says
Sep 27 / TheStreet.com - Paid Partner Content
Mylan (MYL) Accounted for a U.S. Tax Rate in the Profitability of the EpiPen.
Sep 26 / TheStreet.com - Paid Partner Content
Frontrunning: September 27
Sep 27 / Investing Channel - Paid Partner Content
Clinton, Trump Share Big-Pharma Attack Goals, Andrew Left Says
Sep 26 / TheStreet.com - Paid Partner Content
"Hillary Rally" Fizzles As DB Hits New Record Low; Volkswagen Slammed; Oil Slides On ...
Sep 27 / Investing Channel - Paid Partner Content
Trending Tickers: TWTR, VRX, ENDP, RIG
Sep 26 / TheStreet.com - Paid Partner Content
Here's How the Markets Could React to the First Clinton-Trump Presidential Debate
Sep 26 / TheStreet.com - Paid Partner Content
Andrew Left Says Trump and Clinton Agree on Just One Thing
Sep 26 / TheStreet.com - Paid Partner Content
Mylan (MYL) CEO's Testimony Underestimated EpiPen Profits
Sep 26 / Zacks.com - Paid Partner Content
Mylan Admits EpiPen Profits 60% Higher Than It Told Congress, Stock Slips
Sep 26 / Investing Channel - Paid Partner Content

Today’s Trading

Previous close41.31
Today’s open41.18
Day’s range40.04 - 41.43
Volume5,562,094
Average volume (3 months)5,393,144
Market cap$22.1B
Dividend yield--
Data as of 4:14pm ET, 09/28/2016

Growth & Valuation

Earnings growth (last year)-27.35%
Earnings growth (this year)+15.31%
Earnings growth (next 5 years)+9.26%
Revenue growth (last year)+21.91%
P/E ratio17.3
Price/Sales2.84
Price/Book2.08

Competitors

 Today’s
change
Today’s
% change
VRTXVertex Pharmaceutica...-0.28-0.31%
ZTSZoetis Inc-0.12-0.23%
BAXBaxter International...+0.59+1.25%
INCYIncyte Corp+4.13+4.64%
Data as of 4:14pm ET, 09/28/2016

Financials

Next reporting dateOctober 27, 2016
EPS forecast (this quarter)$1.57
Annual revenue (last year)$9.5B
Annual profit (last year)$847.6M
Net profit margin8.95%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chief Executive Officer &
Executive Director
Heather M. Bresch
President &
Executive Director
Rajiv Malik
Corporate headquarters
Hatfield, Hertfordshire

Forecasts

Search for Jobs